跳至主要内容
临床试验/JPRN-jRCTs051230088
JPRN-jRCTs051230088招募中Unknown

The efficacy and safety of remimazolam in endoscopic sedation during endoscopic retrograde cholangiopancreatography

Inatomi osamu0 个研究点目标入组 96 人开始时间: 2023年8月21日最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
96

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • (1)Patients with diseases requiring ERCP.
  • (2)Older than 20years at registration.
  • (3)ECOG-Performance Status is 0 or 1.
  • (4)45 to 80 kg for body weight, under 30kg/m2 for BMI
  • (4)No restrictions for Remimazolam.(allergy, acute angle-closure glaucoma, myasthenia gravis, shock, coma, acute alcoholism)
  • (5)Patients who have informed consent after receiving a sufficient explanation about their participation in the study.

排除标准

  • (1)Patients with a history of hypersensitivity to remimazolam.
  • (2)Patients with acute angle-closure glaucoma
  • (3)Patients with myasthenia gravis
  • (4)Patients with serious complications in other organs: ASA classification 3 or higher (excluding dialysis patients)
  • (5)Patients with drug dependence
  • (6)Patients with severe liver dysfunction (Child Pugh classification C)
  • (7)Patients who are pregnant or breastfeeding
  • (8)Other patients who are judged to be inappropriate as subjects by the principal investigator

研究者

发起方
Inatomi osamu

相似试验